Gamida Cell Ltd. Reports FDA Recommending Further Study of StemEx®
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
JERUSALEM--(BUSINESS WIRE)--Gamida Cell announced today that while the current single arm Phase II/III study, incorporating a historical cohort as the study control, provides evidence of activity of StemEx®, the FDA has advised Gamida Cell to conduct another trial – a Phase III, randomized, controlled clinical study.
Help employers find you! Check out all the jobs and post your resume.
JERUSALEM--(BUSINESS WIRE)--Gamida Cell announced today that while the current single arm Phase II/III study, incorporating a historical cohort as the study control, provides evidence of activity of StemEx®, the FDA has advised Gamida Cell to conduct another trial – a Phase III, randomized, controlled clinical study.
Help employers find you! Check out all the jobs and post your resume.